Literature DB >> 27074938

Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination.

Indhira De La Rosa1, Iona M Munjal2, Maria Rodriguez-Barradas1,3, Xiaoying Yu1, Liise-Anne Pirofski2, Daniel Mendoza4,3.   

Abstract

HIV(+) subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27074938      PMCID： PMC4895006          DOI： 10.1128/CVI.00026-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  38 in total

1.  Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Authors:  Lisa A Jackson; Kathleen M Neuzil; Moon H Nahm; Cynthia G Whitney; Onchee Yu; Jennifer C Nelson; Pat T Starkovich; Maya Dunstan; Barbara Carste; David K Shay; James Baggs; George M Carlone
Journal:  Vaccine       Date:  2007-03-12       Impact factor: 3.641

2.  HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.

Authors:  Ryusho Kariya; Manabu Taura; Shinya Suzu; Hirofumi Kai; Harutaka Katano; Seiji Okada
Journal:  Cancer Lett       Date:  2013-09-05       Impact factor: 8.679

3.  Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults.

Authors:  J Hedlund; A Ortqvist; H B Konradsen; M Kalin
Journal:  Scand J Infect Dis       Date:  2000

4.  Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.

Authors:  M A Shelly; H Jacoby; G J Riley; B T Graves; M Pichichero; J J Treanor
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

5.  Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.

Authors:  Maria Letizia Giardino Torchia; Elena Ciaglia; Anna Maria Masci; Laura Vitiello; Manuela Fogli; Andrea la Sala; Domenico Mavilio; Luigi Racioppi
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

6.  An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.

Authors:  P André; M Groettrup; P Klenerman; R de Giuli; B L Booth; V Cerundolo; M Bonneville; F Jotereau; R M Zinkernagel; V Lotteau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

7.  Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.

Authors:  F Ahmed; M C Steinhoff; M C Rodriguez-Barradas; R G Hamilton; D M Musher; K E Nelson
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

8.  A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients.

Authors:  Deepali Kumar; Maggie Hong Chen; Gary Wong; Isabel Cobos; Brenda Welsh; Deborah Siegal; Atul Humar
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

9.  Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.

Authors:  Selma Tobudic; Veronika Plunger; Gere Sunder-Plassmann; Markus Riegersperger; Heinz Burgmann
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

10.  Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.

Authors:  Stephanie Kruetzmann; M Manuela Rosado; Holger Weber; Ulrich Germing; Olivier Tournilhac; Hans-Hartmut Peter; Reinhard Berner; Anke Peters; Thomas Boehm; Alessandro Plebani; Isabella Quinti; Rita Carsetti
Journal:  J Exp Med       Date:  2003-04-07       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.